How Does Sandostatin Work? Mechanism of Action Explained in Plain English

Sandostatin (octreotide) is a man-made version of a natural hormone. Understanding how it works can help you appreciate why it's so effective for conditions like acromegaly, carcinoid syndrome, and neuroendocrine tumors — and why it affects so many different systems in the body.

Step 1: Understanding Somatostatin — The Natural "Off Switch"

Your body naturally produces a hormone called somatostatin. It's made in the hypothalamus (a region of the brain), the pancreas, and the gastrointestinal tract. Think of somatostatin as your body's "off switch" for hormone secretion. When it binds to receptors on nearby cells, it tells those cells to slow down production of their hormones and secretions.

The problem with natural somatostatin is that it's broken down in the bloodstream within minutes. It can't be used as a medication because it would have to be infused continuously to work. That's where octreotide comes in.

Step 2: What Sandostatin Is — A Longer-Lasting Copycat

Sandostatin (octreotide) is a synthetic octapeptide — a chain of 8 amino acids — that mimics the key active portion of natural somatostatin. It was engineered to be much more stable in the body, lasting hours instead of minutes after injection. This makes it practical as a medication.

Octreotide binds primarily to somatostatin receptor subtype 2 (SSTR2), which is the most abundant somatostatin receptor on growth-hormone-producing cells (somatotrophs) in the pituitary and on many neuroendocrine tumor cells. It also binds, to a lesser extent, to SSTR5.

Step 3: How Sandostatin Suppresses Growth Hormone in Acromegaly

In acromegaly, a pituitary tumor (usually an adenoma) produces abnormally high levels of growth hormone (GH). Excess GH causes the liver to produce high levels of insulin-like growth factor 1 (IGF-1), which is responsible for the physical changes of acromegaly — enlargement of the hands, feet, face, tongue, and internal organs.

When Sandostatin binds to SSTR2 receptors on the pituitary tumor cells, it:

• Activates intracellular signaling pathways that reduce cyclic AMP (cAMP) production
• Reduces calcium entry into the cell
• Inhibits exocytosis (the release of hormone-containing vesicles)

The result: GH secretion drops significantly. IGF-1 levels fall. The physical effects of acromegaly slow or stop progressing. In some patients, long-term octreotide therapy also causes mild shrinkage of the pituitary tumor itself.

Step 4: How Sandostatin Controls Carcinoid Syndrome and NETs

Neuroendocrine tumors (NETs) and carcinoid tumors are cancers that arise from hormone-producing cells in the gut, pancreas, lungs, and other tissues. These tumors often express high levels of somatostatin receptors — particularly SSTR2. When they become malignant, they can secrete large amounts of hormones — especially serotonin, histamine, and vasoactive intestinal peptide (VIP) — that cause the disabling symptoms of carcinoid syndrome.

Sandostatin binds to SSTR2 on the tumor cells and suppresses the overproduction and secretion of these hormones. This reduces flushing episodes, diarrhea, and other carcinoid syndrome symptoms. It also has a mild antiproliferative effect — meaning it slows tumor growth — though its primary role in carcinoid syndrome is symptom control.

Step 5: Sandostatin's Broader Effects Throughout the Body

Because somatostatin receptors are found throughout the body, Sandostatin has wide-ranging effects beyond its primary target:

• Pancreas: Suppresses insulin and glucagon secretion (which is why blood sugar monitoring is important). Also reduces pancreatic enzyme and bicarbonate secretion.
• GI tract: Reduces secretion of gastrin, secretin, motilin, and VIP. Slows gastric acid secretion and GI motility. This is why it helps control diarrhea in carcinoid and VIPoma patients.
• Gallbladder: Inhibits gallbladder contractility and reduces bile secretion, explaining the risk of gallstone formation with long-term use.
• Cardiovascular system: Reduces splanchnic blood flow (blood flow to the gut). Can slow heart rate — which is why cardiac monitoring is recommended during IV use.
• Thyroid: Suppresses TSH (thyroid-stimulating hormone), which can lead to hypothyroidism with long-term use.

Why the LAR Formulation Provides Steady Control

The Sandostatin LAR Depot formulation encases octreotide in tiny biodegradable polymer microspheres. When injected into the gluteal muscle, the polymer slowly breaks down over 4 weeks, releasing octreotide at a steady rate. This provides much more consistent blood levels than multiple daily injections — with peak-to-trough variation of 44–68% versus 163–209% for the daily injection. Steady levels mean steadier symptom control.

Understanding how Sandostatin works also explains why its side effects occur. Read our guide on Sandostatin side effects to learn what to watch for. And if you're having trouble locating your prescription, medfinder can help find pharmacies with it in stock.